Role of atazanavir in the treatment of HIV infection

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 99-116

  Rivas, Pablo ^a   Morello, Judit ^a   Garrido, Carolina ^a   Rodríguez Nóvoa, Sonia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Atazanavir; Drug resistance; HIV; Protease inhibitors

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; ATAZANAVIR; BEPRIDIL; CARBAMAZEPINE; CLARITHROMYCIN; FOSAMPRENAVIR; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LIDOCAINE; LOPINAVIR; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; QUINIDINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; TERFENADINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; NAUSEA; NEPHROLITHIASIS; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UROLITHIASIS; VOMITING;

EID: 67650553226     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bristol Myers Squibb Company. Princeton, NJ 08543, USA. Reyataz product information. [Accessed 31 Aug 2008]. Available from: http://packageinserts.bms. com/pi/pi-reyataz.pdf
2. Colonno R, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of HIV type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47(4):1324-1333.
3. Drusano G, Bilello J, Preston S, et al. Hollow-fiber unit evaluation of a new HIV type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis. 2001;183(7):1126-1129.
4. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identifi cation of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189(10):1802-1810.
5. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose ZDV and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-1019.
6. Sista P, Wasikowski B, Lecocq P, Pattery T, Bacheler L. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts. J Clin Virol. 2008;42(4):405-408.
7. De Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses. 2007;23(7):879-885.
8. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16(1):62-68.
9. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5(4):201-205.
10. Stebbing J, Nathan B, Jones R, et al. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS. 2007;21(13):1826-1828.
11. Cuzin L, Flandre P, Pugliese P, et al. Atazanavir in patients with persistent viral replication despite HAART: Results from the French prospective NADIS cohort. HIV Clin Trials. 2008;9(3):147-151.
12. Shafer R, Schapiro J. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev. 2008;10(2):67-84.
13. Lataillade M, Molina JM, Thiry A, Mancini M, McGrath D, for the BMS-AI424138 Study Group. The CASTLE study 48 weeks results: The impact of HIV subtypes and baseline resistance on treatment outcomes and the emergence of resistance. Antivir Ther. 2008;13 suppl 3:A135.
14. Goldsmith D, Perry C. Atazanavir. Drugs. 2003;63(16):1679-93.
15. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with HIV infection. Antimicrob Agents Chemother. 2006;50(11):3801-3808.
16. Rutstein R, Samson P, Kiser J, et al. The PATCG 1020 protocol: Atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. 14th Conference on Retroviruses and Opportunistic Infections (CROI). 2007 February 3-5; Los Angeles, USA; Abstract 715.
17. Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis. 2007;195(7):973-979.
18. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43(15):1071-1087.
19. Eley T, Vandeloise E, Child M, et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily/Ritonavir 100 mg once daily + ZDV/3TC during the third trimester in HIV+ women. 15th Conference on Retroviruses and Opportunistic Infections (CROI). 2008 Feb 3-6; Boston, USA; Abstract 624.
20. Ferreira C, Floch-Tudal C, Meier F, et al. Atazanavir in pregnancy: Influence on neonatal hyperbilirubinemia. 15th Conference on Retroviruses and Opportunistic Infections (CROI). 2008 Feb 3-6; Boston, USA; Abstract 625.
21. Lucia M, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005;39(5):635-637.
22. Perloff E, Duan S, Skolnik P, Greenblatt D, von Moltke L. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005;33(6):764-770.
23. La Prote C, Back D, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3:3-14.
24. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008;1-128. [Accessed 31 August 2008]. Available from: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf
25. Gonzalez de Requena D, Bonora S, Cavechia I. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: Definition of therapeutic range. 6th International Workshop on Clinical Pharmacology of HIV Therapy. April 28-30 2005; Quebec City, Quebec, Canada; Abstract 60.
26. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther. 2006;11(4):421-429.
27. Morse G, Catanzaro L, Acosta E. Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis. 2006;6(4):215-225.
28. Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS. 2005;19(13):1393-1399.
29. Rodriguez Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C ->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42(2):291-295.
30. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21(1):41-46.
31. Rodriguez-Novoa S, Morello J, González M, et al. Increase in serum bilirubin in HIV/HCV coinfected patients on stable atazanavir therapy following initiation of peginterferon plus ribavirin. AIDS. 2008 (in press).
32. Taburet A, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob Agents Chemother. 2004;48(6):2091-2096.
33. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily Atazanavir/ritonavir and twice-daily Lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-718.
34. Rodriguez-Novoa S, Morello J, Barreiro P, et al. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses. 2008;24(6):821-825.
35. Burchell B, Brierley C, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 1995;57(20):1819-1831.
36. Zhang D, Chando T, Everett D, Patten C, Dehal S, Humphreys W. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33(11):1729-1739.
37. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-3478.
38. Kroetz D, Pauli-Magnus C, Hodges L, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13(8):481-494.
39. Lamba J, Strom S, Venkataramanan R, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006;79(4):325-338.
40. Kohle C, Mohrle B, Munzel P, et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol. 2003;65(9):1521-1527.
41. Lankisch T, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006;44(5):1324-1332.
42. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192(8):1381-1386.
43. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32(1):18-29.
44. Murphy R, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17(18):2603-2614.
45. Gallagher D, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon P. Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis. 2008;47(3):e36-8.
46. Busti A, Tsikouris J, Peeters M, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7(5):317-322.
47. Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;21(12):1648-1651.
48. Chang H, Pella P. Atazanavir urolithiasis. N Engl J Med. 2006;355(20):2158-2159.
49. Couzigou C, Daudon M, Meynard J, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45(8):e105-8.
50. von Hentig N. Atazanavir/ritonavir: A review of its use in HIV therapy. Drugs Today (Barc). 2008;44(2):103-132.
51. Malan D, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47:161-167.
52. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA. 2008;300:555-570.
53. Campbell T, Smeaton L, De Grutolla V, et al. PEARLS (ACTG A5175): A multinational study of didanosine-EC, emtricitabine and atazanavir vs co-formulated ZDV/lamivudine and EFV for initial treatment of HIV-1 infection. XVII International AIDS Conference. 2008 Aug 3-8; Mexico City, Mexico; Abstract THAB0404.
54. Smith K, Weinberg W, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.
55. Molina J, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
56. Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS. 2003;17(9):1339-1349.
57. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS. 2004;18(9):1291-1297.
58. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. Curr Med Res Opin. 2005;21(10):1683-1692.
59. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694.
60. de Mendoza C, Valer L, Ribera E, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials. 2006;7(4):163-171.
61. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: A review. New Microbiol. 2007;30(2):79-88.
62. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36(2):684-692.
63. Sension M, Grinsztejn B, Molina JM, et al. AI424067: Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline. 12th Conference on Retroviruses and Opportunistic Infections. 2005 Feb 22-25; Boston, MA, USA; Abstract 858.
64. Bristol-Myers Squibb Company. Clinical Study Report AI424067. [Accessed 31 Aug 2008]. Available from: http://ctr.bms.com/pdf//AI424067.pdf27.
65. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484-1492.
66. Soriano V, Garcia-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial. J Antimicrob Chemother. 2008;61(1):200-205.
67. Mallolas J, Podzamczer D, Domingo P, et al. Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2007 July 22-25; Sydney, Australia; Abstract WEPEB117LB.
68. Noor M, Flint O, Maa J, Parker R. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. AIDS. 2006;20(14):1813-1821.
69. Guffanti M, Caumo A, Galli L, et al. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol. 2007;156(4):503-509.
70. Busti A, Bedimo R, Margolis D, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med. 2008;56(2):539-544.
71. Jemsek J, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and EFV, each administered in combination with ZDV plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42(2):273-280.
72. Haerter G, Manfras B, Mueller M, Kern P, Trein A. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS. 2004;18(6):952-955.
73. Moyle G, Girard J, Andrade J, et al. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. XVII International AIDS Conference. 2008 August 3-8; Mexico City, Mexico; Abstract MOPDB103.
74. Colafigli M, Di Giambenedetto S, Bracciale L, Tamburrini E, Cauda R, De Luca A. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 2008;9(3):172-179.
75. Flammer A, Vo N, Ledergerber B, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: Randomized controlled trial. Heart (in press).
76. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-ofconcept pilot clinical trial (OK study). J Acquir Immune Defic Syndr. 2005;40(3):280-287.
77. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22(2):F1-9.
78. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296(7):806-814.
79. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007;44(4):417-422.
80. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: The atazanavir-ritonavir monomaintenance (ATARITMO) trial. AIDS. 2007;21(10):1309-1315.
81. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev. 2008;10(1):4-14.
82. Vora S, Marcelin AG, Gunthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitorexperienced patients. AIDS. 2006;20(1):35-40.
83. Bertoli A, Santoro MM, Lorenzini P, et al. Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients. Antivir Ther. 2006;11 suppl 1:S99.